Crossject is a new entrant in the supergeneric field. Its differentiating feature is its delivery mechanism, Zeneo, a pretty unique painless injection system. Crossject has completed clinical trials on a first well-known molecule, Methotrexate, with another six to go in the pipeline. Zeneo is the fruit of over 12 years of R&D. It is an automatic, single-use needle-free injection device with a pre-filled container, to be used on the arm, abdomen or thigh.

View fundamental analysis

Retour haut de page